+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Indian Cancer Biomarker Market 2019-2025

  • ID: 5116751
  • Report
  • February 2020
  • Region: India
  • Orion Market Research Private Limited

FEATURED COMPANIES

  • Abbott Laboratories Inc.
  • Astellas Pharma Inc.
  • Becton, Dickson and Co.
  • Danaher Corp.
  • F. Hoffmann-La Roche Ltd.
  • Merck and Co., Inc.
Indian Cancer Biomarker Market Size, Share & Trends Analysis Report by Biomarker Type (Genetic Biomarker, and Protein Biomarker), by Cancer Type (Lung Cancer, Prostate Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer, and Other), by Applications (Drug Discovery and Development, Diagnosis, Risk Assessment, and Prognostics), and by Profiling Technology (Omics Technology, Immunoassays, Cytogenetics, and Bioinformatics) Forecast Period 2019-2025.

Indian cancer biomarker market is expected to grow at a CAGR of around 12.0% during the forecast period. India is a strong market for cancer biomarkers particularly due to its large population base and large mortality due to cancer. Global cancer biomarker market has huge scope in India as biomarker development will enable in screening of large populations. It may depend on the specific use of a cancer biomarker. Earlier diagnosis of cancer through biomarkers will result in the reduction of financial stress over the population and government, minimizing the cost of adverse events. The fast and speedy diagnosis of cancer in country such as India with a population of 1.31 billion is required which can be achieved with biomarker development in the region. Further biomarker applications in diagnosis, monitoring of effects during treatment and surveillance of patients during or following treatment as well as treatment optimization will spur the growth of the market in this region.

There are many Indian companies in the Indian cancer biomarker that are striving to contribute significantly in the landscape. The companies are collaborating with many foreign companies for promoting biomarker and personalized medicine approach for treating cancer. Core Diagnostics, Nutech Cancer Biomarkers, Cancer Genetics, Biogenuix, BioServe Biotechnologies are contributing in the cancer biomarker market in India. In April 2017, Core Diagnostics partnered with a silicon-based life science company called CellMax Life. The objective was to introduce CellMax Life’s genetic cancer risk test and ctDNA-based liquid biopsy in Indian markets for faster diagnosis and cancer treatment. These diagnostic advancements are capable of reducing cancer mortality of India by offering personalized, precision cancer risk assessment and screening. Thus, such initiatives and activities by the companies led to the growth of the Indian cancer biomarker.

Research Methodology:

The market study of the Indian cancer biomarker market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The research team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report is intended for biotechnology companies, research laboratories, pharmaceutical companies, research institutions, hospitals, and other related companies for overall market analysis and competitive analysis. The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation:

1. Indian Cancer Biomarker Market Research and Analysis by Biomarker Type
2. Indian Cancer Biomarker Market Research and Analysis by Cancer Type
3. Indian Cancer Biomarker Market Research and Analysis by Application

4. Indian Cancer Biomarker Market Research and Analysis by Profiling Technology

The Report Covers:
  • Comprehensive Research Methodology of the Indian Cancer biomarker market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the Indian Cancer biomarker market.
  • Insights about market determinants which are stimulating the Indian Cancer biomarker market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Abbott Laboratories Inc.
  • Astellas Pharma Inc.
  • Becton, Dickson and Co.
  • Bio-Rad Laboratories, Inc.
  • Danaher Corp.
  • F. Hoffmann-La Roche Ltd.
  • Merck and Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • QIAGEN GmbH
  • Thermo Fisher Scientific Inc.
Note: Product cover images may vary from those shown